Cochrane · systematic review · CD008320
Pharmacological interventions for pruritus in adult palliative care patients
Boehlke, C, Joos, L, Coune, B, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
61
current version
GRADE rated
22
No studies
38
Included studies
NR
No studies 38 · 62.3%Ungraded 1 · 1.6%Very low 8 · 13.1%Low 12 · 19.7%Moderate 1 · 1.6%High 1 · 1.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsSummary of findings table ‐ GABA‐analogues versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: health problem or population
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ GABA‐analogues vs placebo | no estimate extracted | 5 studies · 297 participants | Moderate Downgraded: imprecision |
Quality of life ‐ not measured Summary of findings table ‐ GABA‐analogues vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ GABA‐analogues vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not reported Summary of findings table ‐ GABA‐analogues vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ GABA‐analogues vs placebo | RR 2.63 [0.76, 9.05] | 1 study · 15 participants | Low Downgraded: imprecision |
Summary of findings table ‐ Gabapentin versus pregabalin for patients with chronic kidney disease (CKD)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Gabapentin vs pregabalin | no estimate extracted | 2 studies · 100 participants | Low Downgraded: risk of bias, imprecision |
Quality of life ‐ not reported Summary of findings table ‐ Gabapentin vs pregabalin | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not reported Summary of findings table ‐ Gabapentin vs pregabalin | no estimate extracted | NR | No studies |
Depression ‐ not reported Summary of findings table ‐ Gabapentin vs pregabalin | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ Gabapentin vs pregabalin | RR 4.7 [0.21, 104.14] | 2 studies · 122 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings table ‐ Kappa‐opioid agonists versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Kappa‐opioid agonists vs placebo | no estimate extracted | 6 studies · 1292 participants | High |
Quality of life ‐ not measured Summary of findings table ‐ Kappa‐opioid agonists vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Kappa‐opioid agonists vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Kappa‐opioid agonists vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse drug reaction (ADR) per patient Summary of findings table ‐ Kappa‐opioid agonists vs placebo | RR 1.73 [1.2, 2.48] | 5 studies · 1344 participants | Low Downgraded: imprecision, inconsistency |
Summary of findings table ‐ Ondansetron versus placebo for patients with chronic kidney disease (CKD) and cholestatic (CP)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Ondansetron vs placebo | no estimate extracted | 4 studies · 202 participants | Low Downgraded: imprecision, inconsistency |
Quality of life ‐ not measured Summary of findings table ‐ Ondansetron vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Ondansetron vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Ondansetron vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ Ondansetron vs placebo | RR 2.54 [0.38, 16.78] | 3 studies · 174 participants | Very low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Montelukast versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Montelukast vs placebo | no estimate extracted | 2 studies · 87 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life ‐ not measured Summary of findings table ‐ Montelukast vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Montelukast vs placebo | no estimate extracted | NR | No studies |
depression ‐ not measured Summary of findings table ‐ Montelukast vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per participant ‐ not measured Summary of findings table ‐ Montelukast vs placebo | no estimate extracted | NR | No studies |
Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prurits Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo | no estimate extracted | 4 studies · 212 participants | Low Downgraded: risk of bias, imprecision |
Quality of life ‐ not measured Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo | no estimate extracted | NR | No studies |
Adverse events ‐ not measured Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo | no estimate extracted | NR | No studies |
Summary of findings table ‐ Zinc sulphate versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Zinc sulphate vs placebo | no estimate extracted | 2 studies · 76 participants | Low Downgraded: imprecision |
Quality of life ‐ not measured Summary of findings table ‐ Zinc sulphate vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Zinc sulphate vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Zinc sulphate vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per participant Summary of findings table ‐ Zinc sulphate vs placebo | no estimate extracted | 2 studies · 160 participants | Ungraded |
Summary of findings table ‐ Cromolyn sodium versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Cromolyn sodium vs placebo | no estimate extracted | 2 studies · 100 participants | Very low Downgraded: imprecision, inconsistency |
Quality of life ‐ not measured Summary of findings table ‐ Cromolyn sodium vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Cromolyn sodium vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Cromolyn sodium vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ Cromolyn sodium vs placebo | RR 1.28 [0.02, 106.52] | 2 studies · 122 participants | Very low Downgraded: imprecision, inconsistency |
Summary of findings table ‐ Topical capsaicin versus placebo for patients with chronic kidney disease (CKD)‐associated pruritus
Population: patients with chronic kidney disease (CKD) pruritus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Topical capsaicin vs placebo | no estimate extracted | 2 studies · 112 participants | Low Downgraded: imprecision |
Quality of life ‐ not measured Summary of findings table ‐ Topical capsaicin vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Topical capsaicin vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Topical capsaicin vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ Topical capsaicin vs placebo | RR 3.69 [1.17, 11.67] | 3 studies · 116 participants | Low Downgraded: imprecision |
Summary of findings table ‐ Naltrexone versus placebo for patients with cholestatic pruritus (CP)
Population: patients with cholestatic pruritus (CP)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PruritusScale from: 0 to 10 Summary of findings table ‐ Naltrexone vs placebo | no estimate extracted | 2 studies · 52 participants | Low Downgraded: imprecision, inconsistency |
Quality of life ‐ not measured Summary of findings table ‐ Naltrexone vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Naltrexone vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Naltrexone vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ Naltrexone vs placebo | RR 2.67 [1.32, 5.39] | 1 study · 40 participants | Low Downgraded: imprecision |
Summary of findings table ‐ Rifampin/rifampicin versus placebo for patients with cholestatic pruritus (CP)
Population: patients with cholestatic pruritus (CP)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus Summary of findings table ‐ Rifampin/rifampicin vs placebo | no estimate extracted | 2 studies · 42 participants | Very low Downgraded: imprecision, inconsistency |
Quality of life ‐ not measured Summary of findings table ‐ Rifampin/rifampicin vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction ‐ not measured Summary of findings table ‐ Rifampin/rifampicin vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Rifampin/rifampicin vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient Summary of findings table ‐ Rifampin/rifampicin vs placebo | RR 0.29 [0.03, 2.51] | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Flumecinol versus placebo for patients with cholestatic pruritus (CP)
Population: patients with cholestatic pruritus (CP)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pruritus: significant improvement Summary of findings table ‐ Flumecinol vs placebo | RR 2.32 [0.54, 10.1] | 2 studies · 69 participants | Very low Downgraded: imprecision, inconsistency |
Pruritus Summary of findings table ‐ Flumecinol vs placebo | no estimate extracted | 1 study · 50 participants | Low Downgraded: imprecision |
Quality of life Summary of findings table ‐ Flumecinol vs placebo | no estimate extracted | 1 study · 50 participants | Low Downgraded: imprecision |
Patient satisfaction ‐ not measured Summary of findings table ‐ Flumecinol vs placebo | no estimate extracted | NR | No studies |
Depression ‐ not measured Summary of findings table ‐ Flumecinol vs placebo | no estimate extracted | NR | No studies |
Risk for at least one adverse event per patient ‐ not measured Summary of findings table ‐ Flumecinol vs placebo | no estimate extracted | NR | No studies |